pre-seed
Stage
About
Klothea Bio is a preclinical biotechnology company developing mRNA-based therapeutics aimed at increasing endogenous Klotho protein levels to delay age-related diseases and improve health span, with plans to start Phase 1 clinical trials in early 2026.
Explore Klothea Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.